OncoGenex Technologies Inc. is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.OncoGenex.ca.
This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including statements concerning the proposed
merger between Sonus and OncoGenex. These statements are based on
management's current expectations and beliefs and are subject to a number
of risks, uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking statements.
All statements other than statements of historical fact are statements that
could be deemed forward-looking statements. For example, statements of
expected synergies, the strength of the combined oncology product pipeline,
the timing of clinical trials and development efforts, the results of
clinical and pre-clinical studies, the timing of closing, execution of
integration plans and management and organizational structure are all
forward-looking statements. The potential risks and uncertainties include,
among others, the possibility that the merger does not close or that the
closing may be delayed, synergies and costs savings will not be achieved or
that the companies are unable to su
|SOURCE OncoGenex Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved